AbbVie 미래 성장

Future 기준 확인 4/6

AbbVie (는) 각각 연간 27.6% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 27.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 433.8% 로 예상됩니다.

주요 정보

27.6%

수익 성장률

27.6%

EPS 성장률

Biotechs 수익 성장	35.4%
매출 성장률	6.0%
향후 자기자본 수익률	433.8%
애널리스트 커버리지	Good
마지막 업데이트	04 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

NEOE:ABBV - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	63,019	14,180	26,587	N/A	24
12/31/2025	58,903	11,900	25,295	N/A	26
12/31/2024	55,973	8,099	17,675	N/A	23
9/30/2024	55,533	5,079	N/A	N/A	N/A
6/30/2024	55,000	5,298	17,780	18,638	N/A
3/31/2024	54,403	5,951	21,891	22,686	N/A
12/31/2023	54,318	4,820	22,062	22,839	N/A
9/30/2023	55,138	6,470	24,729	25,514	N/A
6/30/2023	56,023	8,635	24,799	25,542	N/A
3/31/2023	56,741	7,535	23,520	24,228	N/A
12/31/2022	58,054	11,782	24,248	24,943	N/A
9/30/2022	57,819	13,343	21,921	22,590	N/A
6/30/2022	57,349	12,569	22,214	22,923	N/A
3/31/2022	56,725	12,407	22,047	22,808	N/A
12/31/2021	56,197	11,468	21,990	22,777	N/A
9/30/2021	55,169	7,465	21,677	22,556	N/A
6/30/2021	53,729	6,599	19,572	20,451	N/A
3/31/2021	50,195	5,092	17,789	18,650	N/A
12/31/2020	45,804	4,556	16,790	17,588	N/A
9/30/2020	40,650	7,324	15,327	16,009	N/A
6/30/2020	36,227	6,906	14,115	14,734	N/A
3/31/2020	34,057	8,395	13,552	14,122	N/A
12/31/2019	33,266	7,842	12,772	13,324	N/A
9/30/2019	32,867	3,232	12,929	13,441	N/A
6/30/2019	32,624	4,093	12,770	13,410	N/A
3/31/2019	32,647	5,333	13,173	13,799	N/A
12/31/2018	32,753	5,657	12,789	13,427	N/A
9/30/2018	32,187	7,531	11,922	12,619	N/A
6/30/2018	30,946	6,419	N/A	11,366	N/A
3/31/2018	29,612	6,352	N/A	10,503	N/A
12/31/2017	28,216	5,283	N/A	9,960	N/A
9/30/2017	27,273	6,615	N/A	8,917	N/A
6/30/2017	26,710	6,582	N/A	7,100	N/A
3/31/2017	26,218	6,278	N/A	7,015	N/A
12/31/2016	25,638	5,923	N/A	7,041	N/A
9/30/2016	25,242	6,048	N/A	7,463	N/A
6/30/2016	24,754	5,690	N/A	8,164	N/A
3/31/2016	23,777	5,448	N/A	8,078	N/A
12/31/2015	22,859	5,118	N/A	7,535	N/A
9/30/2015	21,911	2,790	N/A	4,994	N/A
6/30/2015	20,986	2,064	N/A	4,625	N/A
3/31/2015	20,437	1,802	N/A	4,510	N/A
12/31/2014	19,960	1,765	N/A	3,549	N/A
9/30/2014	19,619	3,686	N/A	5,372	N/A
6/30/2014	19,258	4,144	N/A	5,384	N/A
3/31/2014	19,024	4,114	N/A	5,704	N/A
12/31/2013	18,790	4,102	N/A	6,267	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ABBV 의 연간 예상 수익 증가율( 27.6% )이 saving rate( 2.2% 보다 높습니다. ).

수익 vs 시장: ABBV 의 연간 수익( 27.6% ) Canadian 시장( 16.2% 보다 빠르게 성장할 것으로 예상됩니다. 16.2% 연간).

고성장 수익: ABBV 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ABBV 의 수익(연간 6% ) Canadian 시장( 6.9% 보다 느리게 성장할 것으로 예상됩니다. 6.9% 연간).

고성장 수익: ABBV 의 수익(연간 6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ABBV 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 433.8 %).

AbbVie 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Recent updates

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견